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Introduction
Frequently, the prostate benign and malignant prolifera-
tions are accompanied by inflammatory processes. The link 
between inflammation and cancer, studied very intense-
ly in the last years, was identified 150 years ago, when in 
1863, Virchow, noticed that cancer tends to occur in sites 
of chronic inflammation. While recently, increased the 
number of researches which demonstrate that acute inflam-
mation contributes to cancer regression [1], there are mul-
tiple epidemiological studies claiming that chronic inflam-
matory diseases are frequently associated with an increased 
risk of cancer [1-3]. Inflammatory foci are dominated by 
multiple immune cells, such as: macrophages, lymphocytes, 
plasma cells, mast cells, etc. 
From this wide range of cells, macrophages represent 
an important component of the tumor inflammatory in-
filtrate [2, 4]. Macrophages, as well as other inflammatory 
cells generate a large amount of growth factors, cytokines 
and chemokines that can cause irreversible DNA damage. 
Moreover, the macrophages can act as pro-inflammatory or 
anti-inflammatory cells, depending on the type of stimu-
lus received from the neighboring microenvironment. In 
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Abstract
Background: Immune cells interact not only with tumor cells but also with stromal cells facilitating the progression of neoplasia. The ongoing battle 
between immune cells and the tumor is an important factor influencing the clinical course and outcome of treatment in various types of cancer. The aim 
of the study was to identify the prognostic value of dendritic cells and macrophages in prostate carcinoma.
Material and methods: This retrospective study analyzed 73 samples of prostate cancer. The macrophages and dendritic cells have been evaluated using 
the immunohistochemical methods with CD68 (macrophages) and S100 (dendritic cells). Macrophages were quantified as intratumoral and peritumoral, 
and dendritic cells – intraepithelial and stromal. The results were analyzed statistically.
Results: For evaluation of the prognostic impact of immune cells was accomplished a correlation between the total number of CD68+/S100+ cells and 
the Gleason score. Thus, statistically significant correlations were obtained both for CD68+ cells (intratumoral p=0.008, peritumoral p=0.001), and for 
S100+ cells (intraepithelial p=0.036, stromal p=0.042). In addition, a statistically significant positive linear correlation was observed between the density 
of intraepithelial S100+ cells and intratumoral CD68+ cells (p=0.018).
Conclusions: The increase in the density of S100+ and CD68+ cells, as well as the significant association of their density with the histological degree of 
the tumor allow us to consider these cells as predictive biomarkers in prostate carcinomas.
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general, two major macrophage phenotypes are identified: 
M1 and M2. The M1 macrophages, or classically activated 
macrophages, are aggressive cells, intensively involved in 
phagocytosis, and promotion of Th1 responses. Also, they 
are important inflammatory cytokine secreting cells, such 
as IL-12, IL-18 and IL-23. In tumors, classically activated 
macrophages play an important role in the recognition and 
destruction of cancer cells, and their presence in the tumor 
mass is usually related to a favorable disease prognosis. 
M2 macrophages or alternatively activated macrophages 
are anti-inflammatory cells, actively involved in the ang-
iogenesis and tissue regeneration. They secrete increased 
amounts of IL-10 and other anti-inflammatory cytokines 
[5]. Depending on secreted molecules, are identified several 
subsets of M2 macrophages. 
These are: 1) M2a macrophages – called profibrotic, 
which secrete IL-4 and IL-13; 2) M2b macrophages – con-
tain IC or TLR/IL1-R ligands and are involved in the regu-
lation of immunity and, often, are called regulatory cells; 3) 
M2c macrophages – secrete IL-10 and TGF-β, and some-
times are described as inactivated cells, which are involved 
in suppressing immunity, tissue regeneration and matrix re-
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modeling; 4) M2d macrophages or tumor-associated mac-
rophages (TAM) – increase tumor progression and growth 
by promoting the process of neo-angiogenesis [5].
The tumor microenvironment, significantly affects 
the polarization of macrophages. Growth factors, such as 
CSF-1 (colony stimulating factor 1) and VEGF (vascular 
epithelial growth factor), MCP-1 (chemotactic protein-1 
monocyte), as well as several chemokines CCL can induce 
monocyte chemotaxis in the tumor microenvironment [6]. 
Neutralization of MCP-1 completely blocks the accumula-
tion of macrophages in the tumors [7]. VEGF, in addition 
to its powerful angiogenic role, recruits monocytes into the 
tumor microenvironment. VEGF blockade leads not only to 
the reduction of vascular density, but also to the reduction 
of macrophage infiltrate [8]. Multiple studies have shown 
that the invading property of tumor cells depends largely on 
macrophages. The invasion of tumor cells, mainly, is accom-
panied by directed migration of macrophages [9].
Dendritic cells (DC) represent the most efficient anti-
gen-presenting cells, which have the function of tissue sen-
tinel. They belong to monocyte-macrophage cell lines that 
strongly express the protein S100 [10]. As immature cells, 
they take up the antigens from peripheral tissues, process 
them, and then expose antigen molecules to the membrane 
surface as molecules of the class I and II histocompatibility 
complex [11, 12]. During antigen processing, the dendritic 
cell undergoes the maturation process, which determines 
its migration into the secondary lymphoid organs, where it 
becomes a competent cell in presenting of antigen to T lym-
phocyte. Thus, dendritic cells initiate the special antigen-
specific immune response [13]. Another functional charac-
teristic of dendritic cells is their effective ability to increase 
the immunomodulatory and cytotoxic potential of NK 
cells, which essentially contribute to the removal of tumor 
cells [14-16]. Furthermore, DCs can also directly mediate 
tumor-targeted cytotoxicity [17]. 
The progression of prostate cancer is accompanied by 
a marked suppression of local immunity, which includes 
the apoptotic death of dendritic cells [18]. Tumor cells can 
significantly inhibit the monocyte conversion into the den-
dritic cells. It is also recognized that prostate cancer not only 
destroys mature dendritic cells, but also inhibits their gen-
esis and maturation, leading to decreased production of an-
tigen-presenting cells and inhibition of their functional ac-
tivity [18-20]. The rapid-growing tumors are usually poorly 
infiltrated by DC and unable to trigger DC recruitment and 
activation that result in delayed or insufficient antitumor 
immune responses. However, the mechanisms regulating 
migration and homeostasis within the tumor are not well 
understood.
In this study, we examined the cell population composi-
tion of CD68+ macrophages and S100+ dendritic cells. We 
also examined the prognostic value of these cells and their 
correlation with the proven parameter of the biological ag-
gressiveness of prostate cancer: degree of tumor differentia-
tion. The obtained results could lead to improved therapeu-
tic modalities in patients with prostate cancer.
Material and methods
The study included 73 cases of prostate carcinoma. 
Histological grading of prostate carcinoma is an important 
step in defining the diagnosis and prognosis. Thus, the pros-
tate cancer specimens were divided into 2 groups: acinar and 
non-acinar carcinomas. For the histological differentiation 
of acinar adenocarcinomas, the Gleason score was used. The 
adenocarcinoma specimens were grouped in: well-differen-
tiated (Gleason score 2-5), medium-differentiated (Gleason 
score 6-7) and poorly-differentiated (Gleason score 8- 10). 
Non-acınar carcinomas were considered poorly differenti-
ated cancers. Due to early lysis of the study material, the 
histological pieces were rapidly harvested. The biopsy frag-
ments, after fixation in 10% buffered formalin, were prima-
rily processed following the standard procedures. Sections 5 
μm thick were sliced off each block, which were mounted on 
histological and silanized slides. Histopathological profiling 
was performed on hematoxylin-eosin stained sections.
The immunohistochemical study included 2 mono-
clonal antibodies: anti-CD68 (clone 514H12, predilute, Leica 
Biosystem Newcastle Ltd, Newcastle Upon Tyne, UK) and 
anti-S100 (polyclonal, predilute, Leica Biosystem Newcastle 
Ltd, Newcastle Upon Tyne, UK). The application of primary 
antibodies was preceded by the exposure to Bond Epitope 
Retrieval Solution 2 (20 minutes) for anti-CD68 and Bond 
Enzyme 1 (10 minutes) for anti-S100. Incubation with pri-
mary antibodies was 20 minutes, compatible working sys-
tem was Bond Polymer Refine Detection System (Leica 
Biosystems, Newcastle Upon Tyne, UK) and 3.3” diami-
nobenzidine was the chromogen used. Counterstaining 
was performed with modified Lille’s hematoxylin. The en-
tire immunohistochemical technique was performed with 
DakoCytomation Autostainer. The final product of the reac-
tion entailed staining cell brown. CD68+ macrophages were 
quantified in the peritumoral and intratumoral areas of the 
stroma, and S100+ dendritic cells were counted in both the 
stroma and intraepithelium. Microscopic examination was 
performed using the Nikon Eclipse E600 microscope. 
Assessment of CD68+ macrophages was performed by 
the modified hot spot method. Initially, the highest cell den-
sity field was identified in the studied stromal areas, at the 
microscopic magnification x100, subsequently immuno-
reactive cells were counted in 3 fields, at the microscopic 
magnification x400. The average value of the three fields was 
used as data for analysis. CD68+ macrophages located near 
areas of necrosis or associated with inflammatory infiltrate 
were excluded from the evaluation.
The modified hot spot method was used for the quan-
titative evaluation of S100+ dendritic cells. S100 was also 
expressed by glial cells, and the presence of the chromog-
enic signal in nerve structures was considered as a posi-
tive internal control. Only S100+ dendritic cells, which had 
cytoplasmic extensions, were included in the evaluation. 
After identifying the field with the highest cell density in the 
studied areas, at x100 microscopic magnification, the im-
munoreactive cells were counted in 5 visual fields, at x400 
microscopic magnification.
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Statistical analysis was performed using SPSS13.0 and 
Microsoft Excel 2010 software. Images were taken and proc-
essed using Lucia G system.
Results
Immunohistochemical analysis revealed the non-homo-
geneous and heterogenic character of CD68+ and S100+ 
immune cells distribution. CD68+ cells were preferentially 
located: along the tumor invasion border, in the stroma of 
tumor foci, including in the lumen of transformed acini 
(fig. 1).
The numerical distribution of CD68+ cells varied in the 
studied areas, the highest density being for intratumoral 
areas (tab. 1). Except non-acinar carcinomas, where the 
great density of CD68+ cells was recorded in the peritumoral 
areas.
Table 1
The mean density of CD68+ and S100+ cells in the 
prostate carcinoma specimens and comparison of 
cellular density between the studied areas
n*
CD68+ macrophages S100+dendritic cells
Intratumoral Peritumoral Stroma Intraepithelial
73
72.7±4.7 44.7±5,0 16.0±1.1 22.4±1.3
t = 4.456        p=<0.001 t = 3.963      p=<0.001
*n – the number of cases included in the study, p – value obtained by 
Student test
In relation to the histological types of adenocarcinomas 
was observed a linear increase of CD68+ macrophages, 
both intratumoral and peritumoral (fig. 2). The density of 
CD68+macrophages was relatively uniform, both intratu-
moral and peritumoral, in most of well- and medium-dif-
ferentiated adenocarcinomas. Except four cases (two well-
differentiated and two medium-differentiated carcinomas), 
where the number of intratumoral macrophages ranged 
between 101-186 cells/field. In poorly-differentiated adeno-
carcinomas, the numerical distribution of immunoreactive 
macrophages was much more heterogeneous. It was ob-
served that in five cases (17%) the density of CD68+ cells in 
both studied areas was identical.
Fig. 2.  The mean density of CD68+ cells in prostate carcinoma 
stroma, where: 
G1 – well-differentiated adenocarcinoma, G2 – medium-differenti-
ated adenocarcinoma, G3 – poorly- or undifferentiated adenocarci-
noma, CPa – non-acinar carcinoma, 
*no true differences were established between the compared groups
The stromal CD68+ macrophages of prostate adenocar-
cinomas showed morphological heterogeneity. Thus, two 
distinct cell populations were highlighted:
1. Small-sized cells (mostly) – intensely branched, with 
thin and long cytoplasmic extensions, intensely and weak-
ly granulated cytoplasm, and round, or oval to elongated 
shape;
2. Large-sized cells – characterized by round shape, rare, 
short cytoplasmic extensions, sometimes polynucleated, 
and highly granular cytoplasm.
The distribution of small-sized CD68+ macrophages 
frequently had an infiltrative character, in contrast to large-
sized cells, which were often located alone among stromal 
cells or formed small cell groups in the tumor mass (fig. 3).
Also, numerous CD68+ cells have been observed in: 
most of intravascular tumor emboli and peripheral areas 
 a.                                                                                               b.
 Fig. 1.  Distribution of CD68+ cells in prostate carcinoma, ×10; anti-CD68 immunoreaction, DAB
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of inflammatory infiltrates. A particular aspect was the cir-
cumscription by the CD68+ cells of prostatic sympexions, 
indirectly, that suggest about the changes in the composi-
tion of the glandular secretion. In relation to blood vessels, 
CD68+ macrophages were located in the thickness of the 
vascular wall, less often among endothelial cells. 
Comparing density of macrophages from peritumoral 
areas with intratumoral areas was obtained a partial corre-
lation. In order to evaluate the prognostic impact of mac-
rophages in adenocarcinomas, it was considered appropri-
ate to achieve the correlation between the total number of 
CD68+ cells and the Gleason score, thus obtaining a statis-
tically significant correlation (p=0.001). Splitting down the 
correlation on studied areas were obtained statistically sig-
nificant correlations for both intratumoral – p=0.008, and 
peritumoral – p=0.001.
Distribution of S100+ cells has been studied both in-
traepithelial and stromal. Distribution of immunoreactive 
cells was non-homogeneous in both areas. However, in 
most of prostate carcinomas the high density was record-
ed in the intraepithelial areas (tab. 1). Evaluation of S100+ 
dendritic cells variation in carcinoma groups revealed the 
heterogeneous character for well-differentiated adenocarci-
nomas and the relatively homogeneous character for poorly 
differentiated adenocarcinomas and small cell carcinomas. 
It was observed that starting with the medium-differentiat-
ed carcinomas, the density of S100+ cells was raised for the 
intraepithelial areas (fig. 4).
However, in 13 cases of prostate carcinoma: 7 medium-
differentiated adenocarcinomas (41.2%), 5 poorly-differ-
entiated adenocarcinoma – 16.7%), one case of non-acinar 
carcinoma (8.3%)), high density of dendritic cells was re-
corded for the stromal areas. Also, we noticed that in three 
cases of the total samples with adenocarcinoma (4.1%), the 
density of S100+ cells in both studied areas was identical.
It was interesting to observe some S100+ tumor cells, es-
pecially in the tissue samples of poorly-differentiated and 
non-acinar carcinomas – 16.4% (n = 12), (fig. 5). An ex-
tremely important fact was the observation of S100+ tumor 
cells in the lumen of blood vessels, as well as at the site of 
tumor metastasis into vessel.
In most of specimens, S100+ cells formed the cell clus-
ters, much rarely were located isolate. Frequently, the den-
dritic cell clusters were followed by polymorphonuclear 
cells infiltrate. A particular aspect observed was the pres-
ence of single dendritic cells in the lumen of glandular acini 
and ducts.
S100+ dendritic cells could be characterized as a het-
erogeneous cell population. Heterogeneity is determined 
either by the intensity of immunolabeling (thus, are cells 
that intensely express the marker (mostly) and cells with 
low-intensity) or by cell size (thus, are small and large- sized 
(dominant) cells) (fig. 6).
In order to evaluate the prognostic impact of dendritic 
cells in adenocarcinomas, it was considered appropriate to 
achieve the correlation between the total number of S100+ 
cells and the Gleason score, thus obtaining statistically sig-
nificant correlations both intraepithelial (p=0.036) and 
stromal (p=0.042). In addition, to highlight the interrela-
 a.                                                                                               b.
Fig. 3.  Heterogeneous character of CD68+ cell populations distribution in the stroma of malignant hyperplastic lesions:  
a) infiltrative features of small-sized CD68+ cells; b) comparative distribution of small-sized versus large-sized cells;  
x40; anti-CD68 immunoreaction, DAB
Fig. 4.  Comparative aspect of intraepithelial and stromal positive 
S100+ dendritic cells distribution in prostate carcinomas, 
g1 – well-differentiated adenocarcinoma, g2 – medium-
differentiated adenocarcinoma, g3 – poorly or undifferentiated 
adenocarcinoma, CPa – non-acinar carcinoma or small cell 
carcinoma, p – value obtained by Student test, 
*no true differences were established between the compared groups
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tionships between the immune cells in the adenocarcinoma 
stroma, there were correlated the densities of dendritic cells 
and macrophages, thus, was obtained a statistically signifi-
cant correlation (p=0.018) between S100+ intraepithelial 
dendritic cells and CD68+ intratumoral macrophages.
Discussion
Tumor cells secrete several pro-inflammatory cytokines, 
which promote the infiltration of the tumor microenviron-
ment with various immune cells, such as macrophages, 
neutrophils, NK cells, dendritic cells, mast cells, T and 
B-lymphocytes. Subsequently, the tumor microenviron-
ment facilitates the angiogenesis, proliferation and invasion 
of carcinoma. According to our data, in prostate carcinoma 
the number of macrophages and dendritic cells is increased 
compared to normal prostate tissue. Distribution of mac-
rophages CD68+, especially for intratumoral areas, was 
uneven, which indirectly demonstrates the active involve-
ment of macrophages in the process of tumor initiation and 
progression. The high amount of macrophages was largely 
achieved due of intratumoral macrophages. In addition, a 
linear increase of CD68+ macrophages was noticed in rela-
tion to the histological grade of adenocarcinomas, in both 
intratumoral and peritumoral.
In the literature, there are studies that present similar 
data about the number of macrophages. Thus, Gollapudi et 
al. have demonstrated increased levels of TAM in prostatic 
intraepithelial neoplasia compared to those from benign le-
Fig. 5.  Expression of the S100 marker of tumor cells, ×10, x40; anti-S100 immunoreaction, DAB.
 a.                                                                                               b.
Fig. 6.  Identification of the heterogeneous character of the immunolabeling expression. 
a) cells that highly express the marker S100, b) cells with low-intensity of immunolabeling, ×40; anti-S100 immunoreaction, DAB
32
oriGiNal  researchT. Globa et al. Moldovan Medical Journal. October 2020;63(4):27-34
sions tissues [21]. At the same time, they have reported that 
patients with high Gleason score contain the higher number 
of TAM. Many clinical researches have shown that there are 
various correlations between TAM density and the tumor 
prognosis [22, 23]. It is also very important, that TAMs in 
different tumor compartments, apparently, have opposite 
effects on the progression of prostate cancer [22, 23].
Studying the morphological features of CD68+ cells in 
the prostate carcinoma samples, were observed two differ-
ent cell populations. Some studies have described two dif-
ferent types of macrophages: M1 phenotype, which has an 
anti-tumor effect and M2 phenotype that promotes angio-
genesis, tumor growth and metastasis. Analysis of various 
studies revealed that the density of the M1 macrophages 
could not be considered a prognostic factor, only the M1/
M2 ratio could be a true and independent prognostic factor. 
Cellular and molecular interaction between the M1 and M2 
population has an important determining role for prognosis 
in cancer patients. Tumor-associated macrophages (TAMs) 
mainly represent a variety of the M2 phenotype, although in 
some studies they have been described as a mix of M1 and 
M2 phenotype [24].
Being part of the tumor microenvironment, dendritic 
cells influence in positive or negative way the course of ma-
lignant disease. Several studies have pointed out the central 
role of the dendritic cells in antitumor immunity [25]. Our 
results have shown an increase of dendritic cells density in 
prostate carcinoma tissues compared to normal tissues. The 
numerical difference from the control group was significant. 
In this study, we noticed that the highest degree of infiltra-
tion with S100+ dendritic cells was associated with poorly-
differentiated adenocarcinomas. Thus, our data demon-
strate that the increase of the S100+ dendritic cells density 
in prostate adenocarcinoma is associated with an unfavour-
able prognosis (the evidence was to obtain a statistically sig-
nificant correlation with the Gleason score).
Dendritic cells play a crucial role in many types of hu-
man cancers. Various studies have shown that the presence 
of high intratumoral DC density is associated with a favour-
able prognosis [26]. In addition, there is evidence related to 
the loss of T lymphocyte activation capacity after exposure 
to dendritic cells in contact with tumor cells [27] and/or re-
lated to the loss of their maturation capacity in the absence 
of migration into lymph nodes [28]. Thus, the increase of 
dendritic cells into tumor areas could be associated with an 
unfavorable prognosis. Our results are different from those 
reported about other tumors. So, in gastric and cervical car-
cinomas no significant associations were observed between 
the degree of dendritic cells infiltration and the degree of 
tumor differentiation [29, 30].
The correlation of increased S100+ dendritic cells den-
sity with a good prognosis has been proven in cases of color-
ectal, lung and esophageal cancers [31-33]. For other tumors 
(e.g. squamous cells laryngeal carcinoma) DC infiltration 
does not correlate with histological grade, tumor stage, or 
survival [34]. The prognostic value of S100+ cells for pa-
tients with renal and breast cancer remains limited [35, 36]. 
Studying the dendritic cells morphology in intraepithelial 
and stromal areas led us to assume that two different sub-
populations of DC were highlighted, which differ both in 
maturation and functional status. In our opinion, a particu-
lar interest was represented by the quantitative difference of 
dendritic cells in two studied areas: stromal and intraepithe-
lial. The increased dendritic cells total density was due to the 
increase of intraepithelial DCs number. Increased number 
of intraepithelial dendritic cells had a linear feature, which 
highlight a significant association between the DC density 
and histological grade of the tumor. Following the obtained 
results, we suppouse that S100+ stromal dendritic cells can 
be considered elements of the microenvironment with im-
portant anti-tumor effect, and the decrease of their number 
in prostate adenocarcinoma is an unfavourable prognostic 
factor. At the same time, the increase in the intraepitheli-
al dendritic cells density can be associated with increased 
immune tolerance to antitumor mechanisms. Similar data 
were reported in 2013 by Doros et al. that associated the 
migration of stromal dendritic cells in the tumor areas of 
laryngeal carcinomas with a favourable prognosis [37]. 
Instead, Nagorsen et al. (2007) observed in colorectal car-
cinoma that better survival depends not only on increased 
stromal dendritic cell number from the tumor area but also 
on the increased amount of epithelial DC [38].
Existing vessels in peritumoral tissues can also promote 
tumor vascularization by co-optation – a process in which 
existing vessels are surrounded by tumor cells and used to 
vascularize the tumor. Moreover, our study showed that 
peritumoral macrophages have often been observed in close 
contact with the proliferating endothelial cells of capillar-
ies and smooth muscle cells of arterioles and venules. Also, 
multiple data reported about involvement of dendritic cells 
in the process of angiogenesis. Depending on the specificity 
of the antigenic subset, localization, activation status and 
cytokines, dendritic cells can produce pro- and antiang-
iogenic mediators. Mostly, in vivo studies demonstrated that 
DC, especially immature DC, promote angiogenesis, while 
in vivo data about antiangiogenic activity of these cells are 
limited.
Analyzing comparatively the densities of these immune 
cells, we noted that the expression of CD68 (macrophages) 
was significantly higher than the expression of S100 (den-
dritic cells). In order to highlight the interrelationships be-
tween the immune cells of prostate carcinoma stroma, the 
densities of dendritic cells were correlated with those of 
macrophages. Thus, we obtained statistically significant cor-
relations for both intraepithelial and stromal dendritic cells. 
The presence of increased densities of immune cells in the 
modified prostate tissues suggests that hyperplastic epithe-
lial cells have sufficient immunogenicity to recruit immune 
cells. Antigens, such as PSA (prostate-specific antigen), 
prostate-specific genes C1, C2, C5, PAGE-1, and prostate 
stem cell antigen, can induce local activation and prolifera-
tion of immune cells [39]. In addition, tumor epithelial cells 
also produce multiple cytokines and adhesion molecules 
that recruit more immunocytes to cancer sites. The involve-
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ment of epithelial cells in prostate malignancy processes is 
also supported by our study, which reported in 12 cases of 
prostate adenocarcinoma about tumor cells expression of 
S100 marker. Moreover, the presence of these S100+ tumor 
cells was observed in the areas of tumor invasion, as well as 
in the lumen of vessels.
Conclusions
In conclusion, the present study has shown that chronic 
inflammatory processes of the prostate, especially those in-
volving the intratumoral infiltrates with macrophages and 
dendritic cells, are essential for tumor progression. Thus, 
the increase in the density of S100+ and CD68+ cells, as well 
as the significant association of their density with the histo-
logical degree of the tumor allow us to consider these cells 
to be predictive biomarkers of tumor grade, progression and 
aggressiveness.
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